PMID- 33888521 OWN - NLM STAT- MEDLINE DCOM- 20211213 LR - 20220518 IS - 1399-3003 (Electronic) IS - 0903-1936 (Print) IS - 0903-1936 (Linking) VI - 58 IP - 5 DP - 2021 Nov TI - Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis. LID - 10.1183/13993003.00025-2021 [doi] LID - 2100025 AB - INTRODUCTION: Understanding the psychometric properties of health-related quality of life (HRQoL) questionnaires can help inform selection in clinical trials. Our objective was to assess the psychometric properties of HRQoL questionnaires in bronchiectasis using a systematic review and meta-analysis of the literature. METHODS: A literature search was conducted. HRQoL questionnaires were assessed for psychometric properties (reliability, validity, minimal clinically important difference (MCID) and floor/ceiling effects). Meta-analyses assessed the associations of HRQoL with clinical measures and responsiveness of HRQoL in clinical trials. RESULTS: 166 studies and 12 HRQoL questionnaires were included. The Bronchiectasis Health Questionnaire (BHQ), Leicester Cough Questionnaire (LCQ), Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) and Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) had good internal consistency in all domains reported (Cronbach's alpha>/=0.7) across all studies, and the Quality of Life-Bronchiectasis (QOL-B), St George's Respiratory Questionnaire (SGRQ), Chronic Respiratory Disease Questionnaire (CRDQ) and Seattle Obstructive Lung Disease Questionnaire (SOLQ) had good internal consistency in all domains in the majority of (but not all) studies. BHQ, SGRQ, LCQ and CAT had good test-retest reliability in all domains reported (intraclass correlation coefficient >/=0.7) across all studies, and QOL-B, CRDQ and SOLQ had good test-retest reliability in all domains in the majority of (but not all) studies. HRQoL questionnaires were able to discriminate between demographics, important markers of clinical status, disease severity, exacerbations and bacteriology. For HRQoL responsiveness, there was a difference between the treatment and placebo effect. CONCLUSIONS: SGRQ was the most widely used HRQoL questionnaire in bronchiectasis studies and it had good psychometric properties; however, good psychometric data are emerging on the bronchiectasis-specific HRQoL questionnaires QOL-B and BHQ. Future studies should focus on the medium- to long-term test-retest reliability, responsiveness and MCID in these HRQoL questionnaires which show potential in bronchiectasis. CI - Copyright (c)The authors 2021. FAU - McLeese, Rebecca H AU - McLeese RH AUID- ORCID: 0000-0003-0647-2503 AD - The Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. FAU - Spinou, Arietta AU - Spinou A AUID- ORCID: 0000-0002-3442-4739 AD - Population Health Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. FAU - Alfahl, Zina AU - Alfahl Z AD - The Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. AD - School of Pharmacy, Queen's University Belfast, Belfast, UK. FAU - Tsagris, Michail AU - Tsagris M AD - Dept of Economics, University of Crete, Rethymnon, Greece. FAU - Elborn, J Stuart AU - Elborn JS AD - Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. FAU - Chalmers, James D AU - Chalmers JD AD - Scottish Centre for Respiratory Research, University of Dundee, Dundee, UK. FAU - De Soyza, Anthony AU - De Soyza A AUID- ORCID: 0000-0002-8566-0344 AD - Respiratory Dept, Institute of Cellular Medicine, Newcastle University and Freeman Hospital, Sir William Leech Research Centre, Newcastle upon Tyne, UK. FAU - Loebinger, Michael R AU - Loebinger MR AD - Host Defence Unit, Royal Brompton Hospital, London, UK. FAU - Birring, Surinder S AU - Birring SS AD - Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. FAU - Fragkos, Konstantinos C AU - Fragkos KC AD - Division of Medicine, University College London, London, UK. FAU - Wilson, Robert AU - Wilson R AD - Host Defence Unit, Royal Brompton Hospital, London, UK. FAU - O'Neill, Katherine AU - O'Neill K AD - The Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. AD - Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. AD - These two authors are co-senior authors. FAU - Bradley, Judy M AU - Bradley JM AD - The Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK Judy.Bradley@qub.ac.uk. AD - Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. AD - These two authors are co-senior authors. LA - eng GR - MR/L011263/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20211111 PL - England TA - Eur Respir J JT - The European respiratory journal JID - 8803460 SB - IM MH - *Bronchiectasis MH - Humans MH - Psychometrics MH - *Pulmonary Disease, Chronic Obstructive MH - Quality of Life MH - Reproducibility of Results MH - Surveys and Questionnaires PMC - PMC8581652 COIS- Conflict of interest: R.H. McLeese has nothing to disclose. Conflict of interest: A. Spinou is the developer of the Bronchiectasis Health Questionnaire, one of the questionnaires included in this review. Conflict of interest: Z. Alfahl has nothing to disclose. Conflict of interest: M. Tsagris has nothing to disclose. Conflict of interest: J.S. Elborn reports grants from IMI/European Commission Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis (iABC), Novartis, Polyphor and Alexia, outside the submitted work. Conflict of interest: J.D. Chalmers reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline and Novartis, personal fees from Chiesi, Zambon and Janssen, outside the submitted work. Conflict of interest: A. De Soyza reports other (meeting support) from AstraZeneca, nonfinancial support (in-kind research support) from Novartis, nonfinancial support (meeting support) from Forest labs, personal fees for lectures and advisory board work from Bayer, personal fees for advisory board work from Novartis, other (travel bursary) from Chiesi, Almirall and Boehringer Ingelheim, grants and personal fees for lectures and advisory board work from AstraZeneca, grants from Pfizer, outside the submitted work; has received medical education grant support for a UK bronchiectasis network from GlaxoSmithKline, Gilead, Chiesi and Forest labs; A. De Soyza's employing institution receives fees for his work as coordinating investigator in a phase III trial in bronchiectasis sponsored by Bayer. Conflict of interest: M.R. Loebinger reports personal fees from Insmed, AstraZeneca and Grifols, outside the submitted work. Conflict of interest: S.S. Birring reports grants and personal fees from Merck, personal fees from Bayer, Shionogi and Bellus, outside the submitted work; and has a patent BHQ pending, and a patent LCQ with royalties paid. Conflict of interest: K.C. Fragkos has nothing to disclose. Conflict of interest: R. Wilson has nothing to disclose. Conflict of interest: K. O'Neill has nothing to disclose. Conflict of interest: J.M. Bradley has nothing to disclose. EDAT- 2021/04/24 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/11/11 CRDT- 2021/04/23 05:45 PHST- 2021/01/06 00:00 [received] PHST- 2021/04/02 00:00 [accepted] PHST- 2021/04/24 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/04/23 05:45 [entrez] PHST- 2021/11/11 00:00 [pmc-release] AID - 13993003.00025-2021 [pii] AID - ERJ-00025-2021 [pii] AID - 10.1183/13993003.00025-2021 [doi] PST - epublish SO - Eur Respir J. 2021 Nov 11;58(5):2100025. doi: 10.1183/13993003.00025-2021. Print 2021 Nov.